Ebselen: prospective therapy for cerebral ischaemia

Bibliography

• SCATTON B: Excitatory amino acid receptor antago- nists: a novel treatment for ischemic cerebrovascular diseases. Life Sciences (1994) 55:2115–2124.
   PubMed Web of Science ®Google Scholar
• PULSINELLI W: Pathophysiology of acute ischemic stroke. Lancet (1992) 339:533–537.
   PubMed Web of Science ®Google Scholar
• •Excellent overview of the problem.
   Google Scholar
• TUHRIM S, HOROWITZ DR, SACHER M, GODBOLD JH: Volume of ventricular blood is an important determi-nant of outcome in supratentorial intracerebral hemorrhage. CriL Care Med. (1999) 27:617–621.
   PubMed Web of Science ®Google Scholar
• OZBEN T: Pathophysiology of cerebral ischemia. Mechanisms involved in neuronal damage. In: Free Radicals, Oxidative Stress, and Anti-oxidants. Pathological and Physiological Significance. özben T (Ed.), Plenum Press, New York and London (1998):163–193.
   Google Scholar
• ••Review covering potential biochemical mechanisms incerebral ischaemia.
   Google Scholar
• TRAYSTMAN RJ, KIRSCH JR, KOEHLER RC: Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J. AppL Physiol. (1991) 71:1185–1192.
   PubMed Web of Science ®Google Scholar
• DUCROCQ C, BLANCHARD B, PIGNATELLI B, OHSHIMA H: Peroxynitrite: an endogenous oxidizing and nitrating agent. Cell. Mol. Life Sci. (1999) 55:1068–1077.
   PubMed Web of Science ®Google Scholar
• BIZJAK ED, MAURO VF: Thrombolytic therapy: a review of its use in acute myocardial infarction. Ann. Pharma-cother. (1998) 32:769–784.
   PubMed Web of Science ®Google Scholar
• NUNN CM, O'NEILL WW, ROTHBAUM D et al.:Long-term outcome after primary angioplasty in myocardial infarction (PAI-0 trial. J. Am. Coll. Cardiol. (1999) 33:640–646.
   Google Scholar
• NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE T-PA STROKE STUDY GROUP: Tissue plasminogen activator for acute ischemic stroke. N Engl. J. Med. (1995) 333:1581–1587.
   PubMed Web of Science ®Google Scholar
• KOROSHETZ WJ, MOSKOWITZ MA: Emerging treatments for stroke in humans. Trends Pharmacol ScL (1996) 17:227–233.
   PubMed Web of Science ®Google Scholar
• •Deals with most major research approaches to stroke therapy.
   Google Scholar
• DICHEK B: Making headway in an untapped market. Scrip Magazine (1998) December 43–45.
   Google Scholar
• MOLLER A, CADENAS E, GRAF P, SIES H: A novel biologi-cally active seleno-organic compound. I. Glutathione peroxidase-like activity in-vitro and antioxidant capacity of PZ 51 (ebselen). Biochem. Pharmacol. (1984) 33:3235–3239.
   Google Scholar
• •First report on GPx-like action of ebselen.
   Google Scholar
• WENDEL A, FAUSEL M, SAFAYHI H, TIEGS G, OTTER R: A novel biologically active seleno-organic compound. II. Activity PZ 51 in relation to glutathione peroxidase. Biochem. Pharmacol. (1984) 33:3241–3245.
   Google Scholar
• •First report on the independence of the GPx-like action of ebselen of free bioavailable selenium.
   Google Scholar
• MAIORINO M, ROVERI A, URSINI F: Antioxidant effect of ebselen (PZ51): Peroxidase mimetic activity on phospholipid and cholesterol hydroperoxides vs. free radical scavenger activity. Arch. Biochem. Biophys. (1992) 295:404–409.
   PubMed Web of Science ®Google Scholar
• •Describes the reactivity of ebselen with phospholipid hydroperoxides.
   Google Scholar
• SIES H: Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Rad. Biol. Med. (1993) 14:313–23.
   PubMed Web of Science ®Google Scholar
• ••Review of the initial work on the biochemical mechanism ofaction and pharmacology of ebselen.
   Google Scholar
• MASUMOTO H, SIES H: The reaction of ebselen with peroxynitrite. Chem. Res. Toxicol (1996) 9: 262–267.
   PubMed Web of Science ®Google Scholar
• MASUMOTO H, KISSNER R, KOPPENOL WH, SIES H: Kinetic study of the reaction of ebselen with peroxyni-trite.FEBS Lett. (1996) 398:179–182.
   PubMed Web of Science ®Google Scholar
• ARTEEL GE, BRIVIBA K, SIES, H: Protection against peroxynitrite. FEBS Lett. (1999) 445:226–233.
   PubMed Web of Science ®Google Scholar
• WENDEL A, OTTER R, TIEGS G: Inhibition by ebselen of microsomal NADPH-cytochrome P 450-reductase in vitro but not in vivo. Biochem. Pharmacol. (1986) 35:2995–2997.
   PubMed Web of Science ®Google Scholar
• SCHEWE C, SCHEWE T, WENDEL A: Strong inhibition ofmammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione. Biochem. Pharmacol. (1994) 48:65–74.
   PubMed Web of Science ®Google Scholar
• SCHEWE T: Molecular actions of ebselen - an antiin-flammatory antioxidant. Gen. Pharmacol. (1995) 26:1153–1169.
   PubMedGoogle Scholar
• •Comprehensive review of inhibitory effects of ebselen on enzymes.
   Google Scholar
• PARNHAM MJ, GRAF E: Pharmacology of synthetic organic selenium compounds. Prog. Drug Res. (1991) 36:9–47.
   PubMedGoogle Scholar
• ••Extensive review of pharmacology of various organicselenum compounds.
   Google Scholar
• Lesser R, Weiss R: Vber selenhaltige aromatische Verbindungen (VD. Chem. Berichte (1924) 57:1077–1082.
   Google Scholar
• •First report on the synthesis of ebselen.
   Google Scholar
• WEBER R, RENSON M: Les chlorures de chloro-3 benzisosélénazolium-1,2: synthese, hydrolyse, thiola-tion, ammonolyse. Bull. Soc.Chim.France (1976) 2/8:1124–1126.
   Google Scholar
• FISCHER H, DEREU N: Mechanism of the catalyticreduction of hydroperoxides by ebselen: A selenium - 77 NMR study. Bull. Soc. Chim. Belg. (1987) 96:757–768.
   Google Scholar
• •Pivotal study of the catalytic action of ebselen.
   Google Scholar
• CANTINEAU R, THIANGE G, PLENEVAUX A, CHRISTIAENS L, GUILLAUME M: Synthesis of 755e-2-phenyl-1, 2-benzisoselenazol-3(21)-one (PZ 51, ebselen). A novel biologically active organo-selenium compound. J. Label]. Comp. Radiopharmaceut. (1986) 23:59–65.
   Google Scholar
• LAMBERT C, CANTINEAU R, CHRISTIAENS L, BIEDER-MANN J, DEREU N: Syntheses and spectral characteriza-tion of the metabolites of a new organo-selenium drug: Ebselen. Bull. Soc. Chim. Belg. (1987) 96:383–389.
   Google Scholar
• ENGMAN L, HALLBERG A: Expedient synthesis of ebselen and related compounds. J. Org. Chem. (1989) 54:2964–2966.
   Web of Science ®Google Scholar
• WILSON SR, ZUCKER PA, HUANG R-RC, SPECTOR A: Development of synthetic compounds with glutathione peroxidase activity. J. Am. Chem. Soc. (1989) 111:5936–5939.
   Web of Science ®Google Scholar
• COTGREAVE IA, MOLDEUS P, BRATTSAND R, HALLBERGA ANDERSSON, CM, ENGMAN L: Alpha-(phenylsele-nenyDaceto-phenone derivates with glutathione peroxidase-like activity. Biochem. Pharmacol (1992) 43:793–802.
   PubMed Web of Science ®Google Scholar
• CHAUDIERE J, YADAN J-C, ERDELMEIER I, TAILHAN-LOMONT C, MOUTET, M: Design of new selenium-containing mimics of glutathione peroxidase. In: Oxidative Processes and Anti-oxidants. Paoletti et al. (Eds.) Raven Press, New York (1994):165–184.
   Google Scholar
• MAY SW: Selenium-based drug design: rationale and therapeutic potential. Exp. Opin. Invest. Drugs (1999) 8:1017–1030.
   PubMedGoogle Scholar
• FLOHE L: The selenoprotein glutathione peroxidase.In: Glutathione. Dolphin D, Poulson R, Avramovic 0 (Eds.) John Wiley & Sons, New York (1989):643–731.
   Google Scholar
• •Comprehensive review of the subject.
   Google Scholar
• MILLS GC: Hemoglobin catabolism. I. Glutathioneperoxidase, an erythrocyte enzyme which protects hemoglobin from oxidase breakdown. J. Biol. Chem. (1957) 229:189–197.
   Google Scholar
• FLOHE L, GeNZLER WA, SCHOCK HH: Glutathione peroxidase: a selenoenzyme. FEBS Lett. (1973) 32:132–134.
   PubMed Web of Science ®Google Scholar
• •First description of GPx as a selenoprotein.
   Google Scholar
• ROTRUCK JT, POPE AL, GANTHER HE, SWANSON AB, HAFEMAN DG, HOEKSTRA WG: Selenium: Biochemical role as a component of glutathione peroxidase. Science (1973) 179:588.
   PubMed Web of Science ®Google Scholar
• URSINI F, MAIORINO M, GREGOLIN C: The selenoen-zyme phospholipid hydroperoxide glutathione peroxidase. Biochim. Biophys. Acta (1985) 839:62–70.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI K, AKASAKA M, YAMAMOTO Y, KOBAYASHI C, MIZOGUCHI J, KOYAMA J: Primary structure of human plasma glutathione peroxidase deduced from cDNA sequences. J. Biochem. (1990) 108:145–148.
   PubMed Web of Science ®Google Scholar
• BRIGELIUS-FLOHE R: Tissue-specific functions of individual glutathione peroxidases. Free Rad. Biol. Med. (1999) 27:951–965.
   PubMed Web of Science ®Google Scholar
• MAIORINO M, ROVERI A, COASSIN M, URSINI F: Kineticmechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51). Biochem. Pharmacol. (1988) 37:2267–2271.
   PubMed Web of Science ®Google Scholar
• MORGENSTERN R, COTGREAVE IA, ENGMAN L: Determi-nation of the relative contributions of the diselenide and selenol forms of ebselen in the mechanism of its glutathione peroxidase-like activity. Chem.-Biol. Interact. (1992) 84:77–84.
   PubMed Web of Science ®Google Scholar
• WILLER A, GABRIEL H, SIES H: A novel biologically active selenoorganic compound. IV. Protective glutathione-dependent effect of PZ 51 (ebselen) against ADP-Fe induced lipid peroxidation in isolated hepatocytes. Biochem. Pharmacol. (1985) 34:1185–1189.
   Google Scholar
• COTGREAVE IA, SANDY MS, BERGGREN M, MOLDEUS PM, SMITH MT: N-acetylcysteine and glutathione dependent protective Effect of PZ 51 (ebselen) against © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3) diquat induced cytotoxicity in isolated hepatocytes. Biochem. Pharmacol. (1987) 36:2899–2904.
   Google Scholar
• HAENEN GRMM, DE ROOIJ BM, VERMEULEN NPE, BAST A: Mechanism of the reaction of ebselen with endoge-nous thiols. Dihydrolipoate is a better cofactor than glutathione in the peroxidase activity of ebselen. Mot. Pharmacol. (1990) 37:412–422.
   Google Scholar
• RAMEZANIAN MS, PADMAJA S, KOPPENOL WH: Nitration and hydroxylation of phenolic compounds by peroxynitrite. Chem. Res. Toxicol (1996) 9:232–240.
   PubMed Web of Science ®Google Scholar
• HAYASHI M, SLATER TF: Inhibitory effects of ebselen on lipid peroxidation in rat liver microsomes. Free Rad. Res. Commun. (1986) 2:179–185.
   PubMedGoogle Scholar
• NARAYANASWAMI V, SIES H: Antioxidant activity of ebselen and related selenoorganic compounds in microsomal lipid peroxidation. Free Rad. Res. Commun. (1990) 10:237–244.
   PubMed Web of Science ®Google Scholar
• NOGUCHI N, YOSHIDA Y, KANEDA H, YAMAMOTO Y, NIKI E: Action of ebselen as an antioxidant against lipid peroxidation. Biochem.Pharmacol. (1992) 44:39–44.
   PubMed Web of Science ®Google Scholar
• PARNHAM MJ, GRAF E: Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions. Biochem.Pharmacol. (1987) 36:3095–4003
   PubMed Web of Science ®Google Scholar
• PARNHAM MJ, LEYCK S, DEREU N, WINKELMANN J, GRAFE: Ebselen (PZ 51)-A GSH-peroxidase-like organosele-nium compound with antiinflammatory activity. Adv. In/Yarn. Res. (1985) 10:397–400.
   Google Scholar
• •Review of initial studies on anti-inflammatory actions of ebselen.
   Google Scholar
• PARNHAM MJ: The pharmaceutical potential of seleno-organic compounds. Exp. Opin. Invest. Drugs (1996) 5:861–870.
   Google Scholar
• HEMLER ME, COOK HW, LANDS WEM: Prostaglandin biosynthesis can be triggered by lipid peroxides. Arch. Biochem. Biophys. (1979) 193:340–345.
   PubMed Web of Science ®Google Scholar
• SCHALKWIJK J, VAN DEN BERG WB, VAN DE PUTTE LBA, JOOSTEN LAB: An experimental model for hydrogen peroxide-induced tissue damage. Effects of a single inflammatory mediator on (perDarticular tissues. Arthr. Rheum. (1986) 29:532–538.
   PubMed Web of Science ®Google Scholar
• GRIFFITH HR, DOWLING EJ, SAHINOGLU T et al.: The selective protection afforded by ebselen against lipid peroxiation in an ROS-dependent model of inflamma-tion. Agents and Actions (1992) 36:107–111.
   PubMedGoogle Scholar
• HARTUNG HP, SCHAFER B, HEININGER K, TOYKA KV: Interference with arachidonic acid metabolism suppresses experimental allergic neuritis. Ann. Neurol. (1986) 20:168.
   Web of Science ®Google Scholar
• OZAKI M, NAKAMURA M, TERAOKA S, OTA K: Ebselen, anovel anti-oxidant compound, protects the rat liver from ischemia-reperfusion injury. Transpl. Int. (1997) 10:96–102.
   PubMed Web of Science ®Google Scholar
• HOSHIDA S, KUZUYA T, NISHIDA M et al: Ebselen protects against ischemia-reperfusion injury in a canine model of myocardial infarction. Am. J. Physiol. (1994) 267: H2342–H2347.
   PubMed Web of Science ®Google Scholar
• MAULIK N, YOSHIDA T, DAS DK: Oxidative stressdeveloped during the reperfusion of ischemic myocar-dium induces apoptosis. Free Radical Biol. Med. (1998) 15:869–875.
   Google Scholar
• RAMAKRISHNAN N, KALINICH JF, MCCLAIN DE: Ebseleninhibition of apoptosis by reduction of peroxides. Biochem. Pharmacol. (1996) 51:1443–1451.
   PubMed Web of Science ®Google Scholar
• TIEGS G, KUSTERS S, KUNSTLE G, HENTZE H, KIEMER AK, WENDEL A: Ebselen protects mice against T cell-dependent, TNF-mediated apoptotic liver injury. J. Pharmacol. Exp. Ther. (1998) 287:1098–1104.
   PubMed Web of Science ®Google Scholar
• DAWSON DA, MASAYASU H, GRAHAM DI, MACRAE IM: The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci. Lett. (1995) 185:65–69.
   PubMed Web of Science ®Google Scholar
• ••Pivotal experimental study of inhibition of cerebralischaemia by ebselen.
   Google Scholar
• TAKASAGO T, PETERS EE, GRAHAM DI, MASAYASU H, MACRAE IM: Neuroprotective efficacy of ebselen, an antioxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. (1997) 122:1251–1256.
   PubMed Web of Science ®Google Scholar
• TAKASE T, OHTA T, OGAWA R et al.: Effect of ebselen on contractile responses in perfused rabbit basilar artery. Neurosurgery (1999) 44:370–377.
   PubMed Web of Science ®Google Scholar
• TAN YX, LI WH, TAO XB, JIANG YY, CHEN WP, ZHOU B: Protection of ebselen against anoxic damage of cultured neurons of cerebral cortex. Chung Kuo Yao Li Hsueh Pao (1997) 18:201–203.
   PubMed Web of Science ®Google Scholar
• WATANABE T, NISHIYAMA M, HORI T, ASANO T, SHIMIZU T, MASAYASU H: Ebselen (DR3305) amelio-rates delayed cerebral vasospasm in a canine two-hemorrhage model. Neurol. Res. (1997) 19:563–565.
   PubMed Web of Science ®Google Scholar
• PARNHAM MJ, BIEDERMANN J, BITTNER CH, DEREU N, LEYCK S, WETZIG H: Structure-activity relationships of a series of anti-inflammatory benzisoselenazolones (BISAs). Agents and Actions (1989) 27:306–308.
   PubMedGoogle Scholar
• TARINO JZ: Evaluation of selected organic and inorganic selenium compounds for selenium-dependent glutathione peroxidase activity. Nutr. Reports Int. (1986) 33:299–306.
   Google Scholar
• MOLLER A, GABRIEL H, SIES H, TERLINDEN R, FISCHER H, ROMER A: A novel biologically active selenoorganic compound. VII. Biotransformation of ebselen in perfused rat liver. Biochem. Pharmacol. (1988) 37:1103–1109.
   PubMedGoogle Scholar
• FISCHER H, TERLINDEN R, LOHR JP, ROMER A: A novelbiologically active selenoorganic compound. VIII. Biotransformation of ebselen. Xenobiotica (1988) 18:1347–1369.
   PubMed Web of Science ®Google Scholar
• SIES, H: Metabolism and disposition of ebselen. In: Selenium in Biology and Medicine. Wendel A (Ed.), Springer-Verlag, Heidelberg (1989) pp:153–162.
   Google Scholar
• NJ, TERLINDEN R, FISCHER H, EVERS M, SIES H: Microsomal metabolism of 2-methylseleno benzanilide. Chem. Res. Toxicol. (1990) 3:199-203. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)
   Google Scholar
• VAN CANEGHEM P: Influences comparatives de différentes substances séléniées et soufrées sur la fragilité des lysosomes et des mitochondries in vitro. Biochem. Pharmacol. (1974) 23:3491–3500.
   PubMedGoogle Scholar
• KAMIGATA N, TAKATA M, MATSUYAMA H, KOBAYASHIM: Novel ring opening reaction of 2-aryl-1,2-benziselenazol-3 (21) -one with thiols. Heterocycles (1986) 24:3027–3030.
   Web of Science ®Google Scholar
• NOMURA H, HAKUSUI H, TAKEGOSHI T: Binding of ebselen to plasma protein. In: Selenium in Biology and Medicine. Wendel A (Ed.), Springer-Verlag, Heidelberg (1989):189–193.
   Google Scholar
• WAGNER G, SCHUCH G, AKERBOOM TP, SIES H: Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem. Pharmacol. (1994) 48:1137–1144.
   PubMed Web of Science ®Google Scholar
• NIKAWA T, SCHUCH G, WAGNER G, SIES H: Interactionof albumin-bound ebselen with rat liver glutathione S-transferase and microsomal proteins. Biochem. Mol. Biol. Int. (1994) 32:291–298.
   PubMedGoogle Scholar
• NIKAWA T, SCHUCH G, WAGNER G, SIES H: Interactionof ebselen with glutathione S-transferase and papain in vitro. Biochem. Pharmacol. (1994) 47:1007–1012.
   PubMed Web of Science ®Google Scholar
• ZIEGLER DM, GRAF P, POULSEN LL, STAHL W, SIES H:NADPH-dependent oxidation of reduced ebselen, 2-selenyl-benzanilide and of 2-(methylse-leno)benzanilide catalyzed by pig liver flavin-containing monooxygenase. Chem. Res. Toxicol. (1992) 5:163–166.
   PubMed Web of Science ®Google Scholar
• DEREU N, FISCHER H, HILBOLL G, ROMER A, TERLINDENR: The use of highly enriched 77Se in metabolic studies of ebselen in man. An NAIR investigation. In: Selenium in Biology and Medicine. Wendel A (Ed.), Springer-Verlag, Heidelberg (1989)163–168.
   Google Scholar
• •Clinical study in a volunteer of metabolism of ebselen labelled in the selenium moiety, clearly establishing that selenium remains within the molecule.
   Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K et al.: Ebselen in acute ischemic stroke. A placebo-controlled, double-blind clinical trial. Stroke (1998) 29:12–17.
   Google Scholar
• ••Pivotal clinical trial.
   Google Scholar
• SAITO I, ASANO T, SANO K et al.: Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after subarachnoid hemorrhage. Neurosurgery (1998) 42:269–278.
   PubMed Web of Science ®Google Scholar
• ••Pivotal clinical trial.
   Google Scholar
• OGAWA A, YOSHIMOTO T, KIKUCHI H et al.: Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc. Dis. (1999) 9:112–118.
   PubMed Web of Science ®Google Scholar
• ••Pivotal clinical trial Michael Parnhaml & Helmut Siest2
   Google Scholar